CellSource Co

CellSource Co Interest Expense

The Interest Expense of CellSource Co (4880.T) as of Nov 20, 2026 is -10.36 M JPY. In the previous year, Interest Expense was 38.45 M JPY — a change of -126.94% (lower).

Interest Expense

-10.36 MJPY

YoY

-126.94%

Last updated:

Interest Expense of CellSource Co is 2025 -10.36 M JPY. Interest Expense of CellSource Co was 2024 38.45 M JPY. It decreases by -126.94% lower compared to the previous year.

The CellSource Co Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-875,000.00 JPY
Jan 1, 2019
-346,000.00 JPY
Jan 1, 2020
-1.89 M JPY
Jan 1, 2021
-6.51 M JPY
Jan 1, 2022
17.46 M JPY
Jan 1, 2023
22.97 M JPY
Jan 1, 2024
38.45 M JPY
Jan 1, 2025
-10.36 M JPY
The CellSource Co Interest Expense history
YEARInterest ExpenseYoY
-10.36 MJPY-126.94%
38.45 MJPY+67.38%
22.97 MJPY+31.55%
17.46 MJPY-368.43%
-6.51 MJPY+244.78%
-1.89 MJPY+445.38%
-346,000.00JPY-60.46%
-875,000.00JPY+174.29%
-319,000.00JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Interest Expense of CellSource Co is -10.36 M JPY in 2025.

Interest Expense of CellSource Co changed from 38.45 M JPY to -10.36 M JPY, representing a -126.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CellSource Co

All Key Metrics — CellSource Co